The effects of botulinum toxin injection during hemorrhoidectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0001141

Enrollment

Registered

2014-06-26

Start date

2014-04-30

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Botulinum toxin A (Botulax®, Hugel pharma co., Ltd, Seoul, Korea) was diluted in saline to a concentration of 50 U/ml. At the end of the operation, each patient received 0.5 ml of solution cont

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with symptomatic third- and fourth-degree hemorrhoids who are candidtates for hemorrhoidectomy

Exclusion criteria

Exclusion criteria: 1. Patients with concomitant anal disease (anal fissure, fistula, abscess, dermatitis, Crohn’s disease, ulcerative colititis) 2. Patients who are on treatment with antipsychotic or anti-anxiety medications 3. Patients who have previous anal operation histories

Design outcomes

Primary

Measure	Time frame
Postoperative pain by pain diary (visual analogue scale; VAS)	—

Secondary

Measure	Time frame
Satisfaction scores after hemorrhoidectomy;Postoperative complications;Anorectal manometry (Preoperative and postoperative);Postoperative wound healing time	—

Countries

Korea, Republic of

Contacts

Public ContactWook Ho Kang

Yang Hospital, Namyangju

Outcome results